Europe approves HMO mix for infant formula
The 6’-SL HMO from Chr. Hansen has been approved for highest use levels in infant formula and follow-on formula in Europe. The HMO 6’-Sialyllactose sodium salt, marketed under the trademark MyOli 6’-SL HMO, is now authorised for the EU market under proprietary protection for five years. The EU authorisation includes the highest use level for 6’-SL in infant formula and follow-on-formula (0.70 g/L) in the EU.
The ingredient may reduce the risk of adhesion of harmful bacteria and proteins during infant brain development by supplying sialic acid, an essential building block for neurons.
Chr. Hansen now has EU authorisation for all five HMOs in its MyOli 5 HMO Mix, which contains 2’-FL, 3-FL, LNT, 3’-SL and 6’-SL.
Jesper Sig Mathiasen, Chr. Hansen HMO senior vice president, said the company can now supply the five HMOs and bring infant nutrition solutions closer to breast milk.
HMOs are the third most abundant solid component of breast milk and are known in many different variations. The benefits stem from the structural diversity of HMOs.
FDA approves three food colours from natural sources
As part of its efforts to phase out synthetic food colours from the nation's food supply, the...
China's new food colouring standard welcomed by industry
China introduced a new standard for food colouring on 1 May, which stipulates that it must be...
Tree sap: a plant-based gelatine alternative?
Researchers from the University of Ottawa may have found a new plant-based alternative to...
